Adverse hemodynamic effects of a selective endothelin ETB receptor antagonist in patients with chronic heart failure:: reversal with a selective endothelin ETA receptor antagonist

被引：0
|
作者：
Cowburn, PJ
Cleland, JGF
McDonagh, TA
McArthur, JD
MacLean, MR
Dargie, HJ
机构：
[1] Univ Glasgow, Glasgow, Lanark, Scotland
[2] Univ Glasgow, Western Infirm, Glasgow G11 6NT, Lanark, Scotland
来源：
CIRCULATION | 1998年 / 98卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3773
引用
收藏
页码：718 / 718
页数：1
相关论文
共 50 条
  • [21] SELECTIVE ENDOTHELIN RECEPTOR (ETA) ANTAGONIST IS NEUROPROTECTIVE IN GERBIL TRANSIENT FOREBRAIN ISCHEMIA
    FEUERSTEIN, GZ
    GU, JL
    OHLSTEIN, EH
    BARONE, FC
    YUE, TL
    STROKE, 1994, 25 (01) : 264 - 264
  • [22] Pharmacological characterization of YM598, a selective endothelin ETA receptor antagonist
    Yuyama, H
    Sanagi, M
    Koakutsu, A
    Noguchi, Y
    Fujimori, A
    Sato, S
    Sudoh, K
    Sasamata, M
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2004, 94 : 267P - 267P
  • [23] Comparison of selective ETA and ETB receptor antagonists in patients with chronic heart failure
    Cowburn, PJ
    Cleland, JGF
    McDonagh, TA
    McArthur, JD
    Dargie, HJ
    Morton, JJ
    EUROPEAN JOURNAL OF HEART FAILURE, 2005, 7 (01) : 37 - 42
  • [24] Aprocitentan Dual endothelin ETA/ETB receptor antagonist Treatment of resistant hypertension
    Warden, B. A.
    Duell, P. B.
    DRUGS OF THE FUTURE, 2021, 46 (08) : 595 - 611
  • [25] Vasodilator effects of the endothelin ETA receptor selective antagonist BMS-193884 in healthy men
    Dhaun, N
    Strachan, FE
    Newby, DE
    Johnston, NR
    Ford, NF
    Hammett, JL
    Palmisano, M
    Webb, DJ
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (06) : 611 - 622
  • [26] Atrasentan - A novel selective endothelin-A receptor antagonist
    Abdelghany, O
    FORMULARY, 2005, 40 (11) : 376 - +
  • [27] HEMODYNAMIC EFFECTS OF TEZOSENTAN, A DUAL ENDOTHELIN RECEPTOR ANTAGONIST, IN PATIENTS WITH CIRRHOSIS
    Lebrec, D.
    Bosch, J.
    Jalan, R.
    Dudley, F. J.
    Jesic, R.
    Garcia-Pagan, J. C.
    Mookerjee, R.
    Moreau, R.
    van Giersbergen, P. L. M.
    Kusic-Pajic, A.
    Dingemanse, J.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S210 - S210
  • [28] Superiority of YM598 over atrasentan as a selective endothelin ETA receptor antagonist
    Yuyama, H
    Noguchi, Y
    Fujimori, A
    Ukai, M
    Fujiyasu, N
    Ohtake, A
    Sato, S
    Sudoh, K
    Sasamata, M
    Miyata, K
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 498 (1-3) : 171 - 177
  • [29] Clinical and hemodynamic effects of an orally active endothelin-1-receptor antagonist in patients with refractory chronic heart failure.
    Suetsch, G
    Christen, S
    Yan, XW
    Strobel, W
    Rickenbacher, P
    Hunziker, P
    Bertel, O
    Kiowski, W
    CIRCULATION, 1997, 96 (08) : 511 - 511
  • [30] Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension
    Williamson, DJ
    Wallman, LL
    Jones, R
    Keogh, AM
    Scroope, F
    Penny, R
    Weber, C
    Macdonald, PS
    CIRCULATION, 2000, 102 (04) : 411 - 418
12345